Back to discover
Drug

Tryptamine

Research stage
Emerging research

Also known as 1H-indole-3-ethanamine, 2-(3-indolyl)ethylamine, 3-(2-Aminoethyl)indole.

RxNorm10897ChEMBLCHEMBL6640UNII422ZU9N5TV
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Tryptamine
Aliases & brands
1H-indole-3-ethanamine2-(3-indolyl)ethylamine3-(2-Aminoethyl)indole
RxNorm CUI
10897
ChEMBL ID
CHEMBL6640
UNII
422ZU9N5TV

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes5
Diabetes Mellitus, Type 21Gastrointestinal Microbiome1Insulin Resistance1Irritable Bowel Syndrome1Metabolic Syndrome1
Journals, researchers & institutions
Top journals
  • Nature communications1
Leading researchers
  • Bian ZX1
  • Gong M1
  • Huang C1
  • Jia W1
  • Lam YY1
  • Lau JY1
  • Lau LT1
  • Lin C1
Leading institutions
free-text, unnormalised
  • Academy of Integrative Medicine1
  • Centre for Chinese Herbal Medicine Drug Development1
  • Department of Biochemistry and Microbiology and New Jersey Institute for Food1
  • Hong Kong Baptist University1
  • Phenome Research Centre1
  • School of Chinese Medicine1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Phenethylamine

Studied across 5 of the same disease areas as Tryptamine in the shared literature.

5 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature